18.2%
Visceral Fat Reduction
Abdominal fat loss at 26 weeks
⚠️ FOR RESEARCH PURPOSES ONLY — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Growth Hormone Releasing Peptide
Tesamorelin
EGRIFTATH9507
A 44-amino acid GHRH analog that stimulates pituitary gh secretion, studied for visceral adipose tissue reduction in clinical research. Premium Research Peptide.
Dosage
Quantity
1
$69.99
4 interest-free payments of $17.50We accept
Tesamorelin$69.99
Free shippingon orders over $150
30-day money-backguarantee
Secure checkout256-bit SSL
117%
IGF-1 Increase
Growth factor elevation
37%
Liver Fat Reduction
NAFLD improvement at 12 months
35%
NAFLD Resolution
Complete fatty liver reversal
P=0.005
Executive Function
Significant cognitive improvement
Mechanism of Action
GHRH Receptor Activation
Binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH release that maintains physiological feedback mechanisms and circadian rhythms.
IGF-1 Mediated Lipolysis
Stimulates hepatic IGF-1 production, promoting selective lipolysis in visceral adipose tissue while preserving subcutaneous fat and muscle mass.
Metabolic Modulation
Reduces ectopic fat deposition in liver and muscle, improving insulin sensitivity and metabolic flexibility without disrupting glucose homeostasis.
Key advantage: Preserves natural GH pulsatility unlike exogenous growth hormone
Clinical Trial Results
Phase 3 EGRIFTA trials in HIV lipodystrophy
18.2%
Average Visceral Fat Reduction at 26 Weeks
VAT Change: Tesamorelin vs Placebo
Tesamorelin 26wk-15.4%
Tesamorelin 52wk-17.5%
Placebo--5%
Trial details: 816 HIV-infected patients with lipodystrophy across two Phase 3 trials. Primary endpoint was percent change in trunk fat (VAT) measured by CT scan at 26 weeks.
Treatment Outcomes
Key Clinical Milestones
Percentage of patients achieving clinical endpoints
73%of participants
Achieved >8% VAT reductionPrimary responders
91.2%of participants
Well toleratedCompleted treatment
52 weeksof participants
Effects maintainedWith continued use
Comparison
VAT Reduction Over Time
Week 26
15.4%%
Week 52
17.5%%
Placebo
-5%%
Beyond Primary Use
Additional metabolic and systemic benefits
108
IGF-1 IncreaseInsulin-like Growth Factor 1
Mean elevation from baseline
Source20
Triglyceride ReductionBlood lipid improvement
In VAT responders
SourcePreserved
Muscle Mass
No loss of lean tissue
SourceImproved
Body Image
Patient-reported outcomes
SourceMetabolic Effects
Lipid & Glucose Metabolism
Improvements in metabolic markers without adverse glucose effects
Triglycerides↓ 20-50 mg/dL
Total Cholesterol↓ 9 mg/dL
Adiponectin↑ 12%
GlucoseNo significant change
Body Composition
Muscle Quality Enhancement
Improvements in muscle density and lean mass area
Trunk Muscle Density
+4.86 HUPsoas Area
+0.46 cm²Rectus Area
+0.44 cm²Hepatic Benefits
Liver Health Markers
Comprehensive improvements in liver function and structure
Hepatic FatMRI-PDFF measurement↓ 37%
Fibrosis ScoreImproved
Gene ExpressionFavorable changes
NASH RiskReduced
Unique benefit: Only FDA-approved agent for HIV-associated NAFLD
Dosing Information
FDA-approved protocols and administration
Tesamorelin requires daily subcutaneous administration. Effects are maintained only with continued treatment and reverse upon discontinuation.
Clinical Protocol
Standard FDA Protocol
For HIV-associated lipodystrophy
1+Week
2mg daily
Subcutaneous injection
AltFORM
1.28mg EGRIFTA WR
Weekly reconstitution option
Inject in abdomen, rotate sites
Same time each day recommended
Effects reverse if discontinued
Continue indefinitely for maintained results
Research Protocol
Cognitive Support Protocol
Based on MCI/aging study
1-20Week
1mg daily
30 min before bedtime
20+Week
Assess response
Lower dose effective
Lower dose than standard lipodystrophy protocol
Bedtime administration studied
Pharmacokinetics
Pharmacokinetic Properties
Bioavailability<4% (typical for peptides)
T½ (half-life)26-38 minutes
Tmax0.15 hours (9 minutes)
MetabolismPeptide hydrolysis
ExcretionRenal (peptide fragments)
Short half-life requires daily dosing
Rapid absorption after SubQ injection
Important Notes
- Monitor IGF-1 levels during treatment
- Assess glucose tolerance periodically
- Not for weight loss management
- Effects not sustained after discontinuation
Safety Profile
Data from Phase 3 trials with 816 patients
Generally well-tolerated with predictable side effects related to GH stimulation. Most adverse events are mild to moderate.
Common Digestive Issues
25%
Injection site reactions
mild
13.3%
Arthralgia
mild
7.5%
Peripheral edema
mild
5.7%
Myalgia
mild
5.1%
Paresthesia
mild
4%
Hypersensitivity
moderate
Immunogenicity
Antibody Development
Anti-tesamorelin antibodies detected but no impact on efficacy
- Does not affect VAT reduction
- Does not alter IGF-1 response
- Clinical significance minimal
Discontinuation Rates
Treatment Discontinuation
Overall AEs8.8%
GH effects4.2%
Injection reactions4.6%
Serious AEs<4%
Most discontinuations in first 26 weeks
Well-tolerated long-term
Important Warnings
Glucose intolerance (5% HbA1c ≥6.5%)
Theoretical malignancy risk with IGF-1 elevation
Diabetic retinopathy progression
Fluid retention complications
Researcher Notes
- Contraindicated in active malignancy
- Caution in patients with diabetes
- Monitor IGF-1 levels regularly
Frequently Asked Questions
Common questions about Tesamorelin
IGF-1 levels increase within 2-4 weeks. Visible reduction in abdominal fat typically begins around 8-12 weeks, with maximal effects at 26 weeks. Clinical trials show 15-18% visceral fat reduction at 6 months.
Effects are not sustained after discontinuation. Clinical studies show visceral fat returns to near baseline levels within 26 weeks of stopping treatment. This makes continuous therapy necessary to maintain benefits.
No. Tesamorelin stimulates your body's own growth hormone production while preserving natural pulsatility and feedback mechanisms. This is physiologically superior to exogenous HGH, which disrupts natural patterns and carries higher risk of side effects.
Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy, not general weight loss. It selectively reduces visceral (abdominal) fat while preserving subcutaneous fat and muscle mass. The FDA label explicitly states it is not for weight loss management.
Regular monitoring includes: IGF-1 levels (should remain in physiological range), glucose tolerance/HbA1c (especially in diabetics), injection site reactions, and periodic assessment of treatment response via waist circumference or imaging.
Research shows promising cognitive benefits. A controlled trial demonstrated significant improvements in executive function (P=0.005) and response inhibition (P=0.009) in both healthy older adults and those with mild cognitive impairment, using just 1mg daily.
Sources & References
Peer-reviewed research
Journal of Clinical Endocrinology & Metabolism
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials
2010•PMID: 20554713
Falutz J, et al.
View Source
Lancet HIVEffects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
2019•PMID: 31611038
Stanley TL, et al.
View Source
⚠️Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
